Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression

NCT01246908 is registered in ClinicalTrials.gov with CeNeRx BioPharma Inc. as lead sponsor.

NCT NCT01246908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01246908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Lead sponsor
CeNeRx BioPharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
May 31, 2012
Enrollment
360 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression